Global Transdermal Drug Delivery Technologies/Systems Market Report 2021 Featuring AbbVie, Dr. Reddy's Laboratories, Bayer, GlaxoSmithKline, J&J, Novartis, Teva Pharmaceutical, and Viatris
Dublin, July 07, 2021 (GLOBE NEWSWIRE) -- The "Global Transdermal Drug Delivery Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global market for transdermal drug delivery systems should grow from $6.4 billion in 2021 to $7.8 billion by 2026, at a compound annual growth rate (CAGR) of 4.2% for the period of 2021-2026.
This report aims to provide a comprehensive study of the global market for transdermal drug delivery technologies/systems. It provides a detailed description of the different types of transdermal drug delivery systems (passive and active) and the current and historical market revenues.
Transdermal drug delivery systems (TDDSs: gels, patches, films, etc.) are placed on the skin and allow specific drug substances to penetrate into the bloodstream through the layers of the skin. TDDSs have many benefits compared to other methods of drug delivery (oral, injectable, etc.)
TDDSs mitigate the hepatic first-pass effect of drugs, offering safety and a better quality of life to the patient. TDDSs are used to treat a wide variety of conditions and diseases, including pain, CNS disorders, hormone imbalance, prevention of nausea and vomiting, cardiovascular diseases (CVD), overactive bladder and several others. Most TDDSs are available in the form of patches.
Transdermal drug delivery (TDD) is still a relative niche segment, currently accounting for a small market share in the overall drug delivery market. However, given the many advantages (ease of use, better patient compliance, improved bioavailability and fewer adverse effects, etc.) over other drug delivery options (oral and injections) TDD has gained increasing attention over the last decade. TDDSs hold huge potential to address the needs of an increasing global elder population, especially in caregiver-intensive conditions and for patients with chronic conditions.
Opportunity exists to translate drug needs into a dosage form that is more end-user (patient) and caregiver friendly. Regarding the patent cliff, TDD could make pharmaceutical companies more competitive. For example, a pharmaceutical company that focuses on life cycle management and TDD as a parallel path during development could be in a better position to extend the life of a drug and to strategically introduce a variety of formulations that drive patient preference.
The advent of innovative, new approaches and continuous technology development is the key factor driving growth in the market. The growing number of elder patients and the increasing demand for convenient drug delivery options with easy self-administration are also facilitating the market growth.
TDD biologics (e.g., peptides, proteins, nucleic acids) and the use of new drug delivery devices such as microneedle systems for transdermal drug delivery, have high growth potential and are likely to have more activity in the coming years. The opportunity areas in this market include TDD of large molecules underpinned by a large (multibillion) biologics market, wherein the demand for advanced drug delivery systems is increasing.
This report also offers a detailed study of therapeutic applications for transdermal drug delivery: pain, central nervous system (CNS) disorders, hormonal applications, smoking cessation, motion sickness, cardiovascular disorders and others. An in-depth analysis of the global market for transdermal drug delivery technologies/systems includes historical data and market projection of sales by technology/system type, therapeutic application, end-user and region.
The Report Includes
Analyses of the global market trends, with data from 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
Market outlook and forecast trends of clinical application areas and end user segments of transdermal drug delivery technologies/systems
Estimation of market size and revenue forecast for TDD market, and corresponding market share analysis by technology/system type, therapeutic application, end-user, and region
Discussion of the key market dynamics (DROs), industry structure, regulatory approval, market deterrents, unmet needs and other factors driving opportunities in pharmaceutical research
Review of patents, new developments and emerging technologies, clinical trials for many pipeline products, and potential markets for future developments
Impact analysis of the Covid-19 pandemic on transdermal drug delivery systems market as against the overall pharmaceuticals industry
Insight into recent industry activities, competitive landscape of the major players operating within the global market, and their corresponding company share analysis
Profile descriptions of the leading drug delivery companies including AbbVie, Dr. Reddy's Laboratories Ltd., Bayer, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Teva Pharmaceutical, and Viatris
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Overview
Mechanism
Advantages
Disadvantages
TDSS Types/Forms
Transdermal Patch
Transdermal Gel
Transdermal Spray
Transdermal Ointment
TDDS Technology Types
Passive TDDS
Types of Passive TDDS
Active TDDSs
Types of Active TDDS
Clinical Application of TDDS
Pain Management
CNS Disorders
Hormonal Applications
Smoking Cessation
Motion Sickness
Cardiovascular Diseases (CVD)
Others
End Users of TDDSs
Home Care Settings
Hospitals and Healthcare Clinics
Chapter 4 Market Breakdown by Technology Type
Passive TDDSs
Active TDDSs
Chapter 5 Market Breakdown by Application
Market Size and Forecast by Therapeutic Application Type
Pain
CNS Disorders
Hormonal Applications
Smoking Cessation
Motion Sickness
CVD
Other Therapeutic Applications for TDDSs
Chapter 6 Market Breakdown by Region
Chapter 7 Market Breakdown by End User
Global Markets for TDDS by End User
Market Size and Forecast by End User
Chapter 8 New Developments and Emerging Technologies
Innovative Transdermal Technologies
Technologies by Hisamitsu Pharmaceutical Co. Inc.
Technologies by 4 P Therapeutics (Nutriband)
Technologies by Corium Inc.
Technologies by Tapemark
Emerging Technologies and Applications for TDDS
Company/System
Chapter 9 Market Dynamics
Market Trends and Growth Drivers
Aging Population
Technology Innovations and New Product Development
Increasing Awareness
Large Unpenetrated Addressable Market
Market Restraining Factors
Product Development and Manufacturing Challenges
The Barrier Nature of the Skin
Side Effects
High Cost of Drug Development and Pricing Pressure
Market opportunity
Repositioning of Currently Marketed Products
Chapter 10 Competitive Landscape
Overview
Key Available TDDSs
Pain Management
Hormone Replacement Therapy
Female Contraception
CNS Disorders
Smoking Cessation
Motion Sickness
For Cardiovascular Diseases
Overactive Bladder
Other Applications
Global Market Shares of Leading Companies
Recent Industry Activities
Product Launches and Approvals
Agreements and Collaborations
Acquisitions and Mergers
Others
Chapter 11 Impact of COVID-19 Pandemic
Chapter 12 Company Profiles
Abbvie Inc.
Acrux Ltd.
Alvogen
Amneal Pharmaceuticals Inc.
Bayer Healthcare Pharmaceuticals
Boehringer Ingelheim International Gmbh
Dr. Reddy's Laboratories Ltd.
Endo Pharmaceuticals Inc.
Glaxosmithkline Plc
Hisamitsu Pharmaceutical Co. Inc.
Johnson & Johnson
Kyowa Kirin Co. Ltd.
Lavipharm S. A.
Luye Pharma Group Ltd.
Novartis Ag
Noven Pharmaceuticals Inc.
Perrigo Company Plc
Purdue Pharma Lp
Tapemark
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Uspharma Ltd.
Vertical Pharmaceuticals Llc
Viatris Inc.
For more information about this report visit https://www.researchandmarkets.com/r/mgsfsa
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900